ContraFect Corporation (CFRX): Price and Financial Metrics


ContraFect Corporation (CFRX)

Today's Latest Price: $5.24 USD

0.05 (0.96%)

Updated Jan 20 6:55pm

Add CFRX to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

CFRX Stock Price Chart Interactive Chart >

Price chart for CFRX

CFRX Price/Volume Stats

Current price $5.24 52-week high $12.10
Prev. close $5.19 52-week low $4.45
Day low $5.18 Volume 105,800
Day high $5.35 Avg. volume 142,642
50-day MA $5.39 Dividend yield N/A
200-day MA $5.72 Market Cap 145.72M

ContraFect Corporation (CFRX) Company Bio

ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. The company was founded in 2008 and is based in Yonkers, New York.

Most Popular Stories View All

• How to Outperform the Stock Market in 2021

• Is Shopify a Smart Buy for 2021?

• 3 Auto Stocks to Buy Instead of Tesla: Ford, GM, and Tata Motors

• Better Buy: Marathon Patent Group vs. Canaan

• 3 Lesser-Known Biotech Stocks that are Surging

View All Top Stories

CFRX Latest News Stream

Event/Time News Detail
Loading, please wait...
View All CFRX News

CFRX Latest Social Stream

Loading social stream, please wait...

View Full CFRX Social Stream

Latest CFRX News From Around the Web

Below are the latest news stories about CONTRAFECT Corp that investors may wish to consider to help them evaluate CFRX as an investment opportunity.

What Kind Of Shareholders Hold The Majority In ContraFect Corporation's (NASDAQ:CFRX) Shares?

Every investor in ContraFect Corporation ( NASDAQ:CFRX ) should be aware of the most powerful shareholder groups...

Yahoo | December 30, 2020

Is CFRX A Good Stock To Buy Now?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

Yahoo | December 11, 2020

CFRX: Enrollment Continues in Phase 3 Trial of Exebacase…

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Exebacase Expanded Access Program Initiated On October 26, 2020, ContraFect Corp. (CFRX) announced the initiation of an expanded access program for exebacase to make it available to COVID-19 patients that are suffering from persistent bacteremia caused by Staphylococcus aureus . Exebacase will be available to use

Yahoo | November 24, 2020

ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients

YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients. Exebacase has been granted Breakthrough Therapy designation for the treatment of MRSA bloodstream infections by the U.S. Food and Drug Administration (FDA). The Company is providing expanded access to exebacase under a treatment protocol available to ...

Yahoo | October 26, 2020

Critical Analysis: NextCure (NASDAQ:NXTC) vs. ContraFect (NASDAQ:CFRX)

NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Earnings and Valuation This table compares NextCure and ContraFect’s top-line revenue, earnings per share and valuation. Gross […]

Dakota Financial News | October 23, 2020

Read More 'CFRX' Stories Here

CFRX Price Returns

1-mo -1.13%
3-mo -2.42%
6-mo -12.67%
1-year -53.83%
3-year -54.83%
5-year -85.64%
YTD 3.76%
2020 -18.64%
2019 -59.43%
2018 51.49%
2017 -42.29%
2016 -63.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7644 seconds.